Covering all the bases: Targeting HIV-1 integrase

Journal of Acquired Immune Deficiency Syndromes

Volumn 43, Issue 5, 2006, Pages 507-508

  Wong, Joseph K ^a,b   Lampiris, Harry ^a,b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYTOCHROME P450 3A4; EFAVIRENZ; ETRAVIRINE; INTEGRASE; INTEGRASE INHIBITOR; L 708906; L 733988; MK 0518; NUCLEOSIDE DERIVATIVE; PLACEBO; VIRUS DNA; VIRUS RNA;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS INHIBITION;

DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; ORGANIC CHEMICALS;

EID: 33845350831     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31802cfeaa     Document Type: Editorial

References (9)

1. Markowitz M, Morales-Ramirez JO, Nguyen B-Y, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43:509-515.
2. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration inhibit HIV-1 replication in cells. Science. 2000;287:646-650.
3. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science. 2004;305:528-532.
4. Ho DD, Neumann AU, Perelson AS, et al Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
5. Louie M, Hogan C, Di Mascio M, et al. Determining the efficacy of highly active antiretroviral therapy. J Infect Dis. 2003;187:896-900.
6. Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetcs, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Research and Human Retroviruses. 2002;18:685-693.
7. Louie M, Hogan C, Hurley A, et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1 infected individuals. AIDS. 2003;17:1151-1156.
8. Markowitz M, Nguyen B-Y, Gotuzzo F, et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment-naive HIV-1 infected patients. XVI, International AIDS Conference. Toronto, Canada, Aug 13-18, 2006.
9. Grinsztejn B, Nguyen B-Y, Katlama C, et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistance virus. 13th Conference on Retroviruses and Opportunistic Infections 2006, Denver, CO.